EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 33 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children July 13, 2018 Hairstylist Creates Custom Wigs & Donates Them To Cancer Patients October 23, 2021 Should People with Cancer and Cancer Survivors Get the Flu Vaccine? September 2, 2020 Mark Hoppus Of Blink-182 Announces He’s Cancer-Free October 8, 2021 Load more HOT NEWS This Program Provides Free Mammograms And Breast Cancer Treatment Services To... Adjuvant mRNA-4157 Plus Pembrolizumab Prolongs RFS versus Pembrolizumab Alone in Patients... High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent... Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic...
